TPST Tempest Therapeutics Corp Company Cash on Hand

The implementation of software robots for data analysis is accelerating drug development, and on GURU.Markets, the cash liquidity of Tempest Therapeutics (TPST) in this context shows that the current amount is 0.00. Tempest Therapeutics (TPST) revenues are based on the commercialization of the drug TPST-1120 for solid tumors. Meanwhile, the potential for pricing power depends directly on future successes in the clinical trials of unique molecules.
Financial and market metric breakdowns for Tempest Therapeutics, Inc. (TPST)

Intensive spending by Tempest Therapeutics (TPST) on clinical trials for oncology drugs is leading to a rapid depletion of liquid reserves. This metric compares the volume of available cash to market capitalization, allowing investors to assess the degree of financial stability and the capital burn rate, which is clearly reflected in the cash-on-hand indicator.